Partners Capital Investment Group LLP Takes $566,000 Position in Urogen Pharma $URGN

Partners Capital Investment Group LLP acquired a new stake in Urogen Pharma (NASDAQ:URGN) in the second quarter, HoldingsChannel reports. The firm acquired 15,384 shares of the company’s stock, valued at approximately $566,000.

Several other hedge funds have also added to or reduced their stakes in URGN. Paradigm Biocapital Advisors LP grew its holdings in Urogen Pharma by 6.1% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after acquiring an additional 257,564 shares during the last quarter. BlackRock Inc. bought a new position in shares of Urogen Pharma during the second quarter valued at $117,814,000. Morgan Stanley raised its stake in shares of Urogen Pharma by 1.4% during the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock valued at $60,023,000 after acquiring an additional 34,455 shares during the last quarter. Soleus Capital Management L.P. acquired a new position in shares of Urogen Pharma during the second quarter worth $29,934,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Urogen Pharma by 20.3% during the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock worth $29,808,000 after purchasing an additional 280,199 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Mark Schoenberg sold 60,677 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider directly owned 59,086 shares of the company’s stock, valued at $2,779,996.30. This represents a 50.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 85,899 shares of company stock worth $3,747,513. 4.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Guggenheim boosted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Friday, July 17th. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. Finally, LADENBURG THALM/SH SH started coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $50.38.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $46.16 on Tuesday. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $50.81. The stock has a 50 day simple moving average of $40.82 and a two-hundred day simple moving average of $29.32. The company has a market cap of $2.26 billion, a P/E ratio of -23.31 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, research analysts predict that Urogen Pharma will post -0.2 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.